Literature DB >> 9102069

A prospective study of thiazide use and fractures in women.

D Feskanich1, W C Willett, M J Stampfer, G A Colditz.   

Abstract

Thiazide diuretics reduce urinary calcium and may inhibit bone resorption, and hence may help to attenuate age-related bone loss and to lower the risk of osteoporotic fracture. We followed 83728 women, who were 36-61 years of age at baseline in 1982, for 10 years with biennial mailed questionnaires on which they reported incident fractures, use of thiazide diuretics, and other medical behavioral information. From descriptions of fracture sites and circumstances, 251 hip (proximal femur) and 1594 forearm (distal radius) fractures were identified as low or moderate trauma events. After controlling for age, body mass index, menopausal status, postmenopausal hormone use, cigarette smoking and dietary factors, we observed a statistically significant 22% reduction in the risk of forearm fractures among current thiazide users compared with women who reported no thiazide use. Risk appeared to decline with longer duration of use, reaching a 37% reduction in risk among women who had been using thiazides for 8 or more years. For hip fractures, thiazide use was protective among the postmenopausal women (relative risk = 0.69, 95% confidence interval 0.48-0.99). We conclude that the potential benefit of thiazide diuretics for osteoporosis should be considered when prescribing antihypertensive treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9102069     DOI: 10.1007/bf01623465

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  26 in total

1.  Effect of chlorothiazide and hydrochlorothiazide on the excretion of calcium in urine.

Authors:  B A LAMBERG; B KUHLBACK
Journal:  Scand J Clin Lab Invest       Date:  1959       Impact factor: 1.713

2.  Risk factors for falls among elderly persons living in the community.

Authors:  M E Tinetti; M Speechley; S F Ginter
Journal:  N Engl J Med       Date:  1988-12-29       Impact factor: 91.245

3.  A longitudinal study of the effect of sodium and calcium intakes on regional bone density in postmenopausal women.

Authors:  A Devine; R A Criddle; I M Dick; D A Kerr; R L Prince
Journal:  Am J Clin Nutr       Date:  1995-10       Impact factor: 7.045

4.  Effect of salt restriction on urine hydroxyproline excretion in postmenopausal women.

Authors:  A G Need; H A Morris; D B Cleghorn; D De Nichilo; M Horowitz; B E Nordin
Journal:  Arch Intern Med       Date:  1991-04

5.  Effect of thiazide on rates of bone mineral loss: a longitudinal study.

Authors:  R Wasnich; J Davis; P Ross; J Vogel
Journal:  BMJ       Date:  1990-12-08

6.  Risk factors for recurrent nonsyncopal falls. A prospective study.

Authors:  M C Nevitt; S R Cummings; S Kidd; D Black
Journal:  JAMA       Date:  1989-05-12       Impact factor: 56.272

7.  Effects of thiazide diuretic therapy on bone mass, fractures, and falls. The Study of Osteoporotic Fractures Research Group.

Authors:  J A Cauley; S R Cummings; D G Seeley; D Black; W Browner; L H Kuller; M C Nevitt
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

8.  Reproducibility and validity of a semiquantitative food frequency questionnaire.

Authors:  W C Willett; L Sampson; M J Stampfer; B Rosner; C Bain; J Witschi; C H Hennekens; F E Speizer
Journal:  Am J Epidemiol       Date:  1985-07       Impact factor: 4.897

9.  Do drugs affect the risk of hip fracture in elderly women?

Authors:  H M Taggart
Journal:  J Am Geriatr Soc       Date:  1988-11       Impact factor: 5.562

10.  Thiazide for the postponement of postmenopausal bone loss.

Authors:  I Transbøl; M S Christensen; G F Jensen; C Christiansen; P McNair
Journal:  Metabolism       Date:  1982-04       Impact factor: 8.694

View more
  29 in total

1.  Drug treatment of hypertension. Conclusion of editorial is somewhat flawed.

Authors:  Daniel G Hackam
Journal:  BMJ       Date:  2003-04-05

2.  Independent association of serum retinol and β-carotene levels with hyperuricemia: A national population study.

Authors:  Woo-Joo Choi; Earl S Ford; Gary Curhan; James I Rankin; Hyon K Choi
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-03       Impact factor: 4.794

Review 3.  Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia.

Authors:  Sirirat Reungjui; Thongchai Pratipanawatr; Richard J Johnson; Takahiko Nakagawa
Journal:  Curr Opin Nephrol Hypertens       Date:  2008-09       Impact factor: 2.894

Review 4.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

5.  Urinary Tract Stones and Osteoporosis: Findings From the Women's Health Initiative.

Authors:  Laura D Carbone; Kathleen M Hovey; Christopher A Andrews; Fridtjof Thomas; Mathew D Sorensen; Carolyn J Crandall; Nelson B Watts; Monique Bethel; Karen C Johnson
Journal:  J Bone Miner Res       Date:  2015-07-14       Impact factor: 6.741

6.  Gout and Risk of Fracture in Women: A Prospective Cohort Study.

Authors:  Julie M Paik; Seoyoung C Kim; Diane Feskanich; Hyon K Choi; Daniel H Solomon; Gary C Curhan
Journal:  Arthritis Rheumatol       Date:  2017-02       Impact factor: 10.995

Review 7.  Idiopathic hypercalciuria and bone health.

Authors:  Laura E Ryan; Steven W Ing
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

8.  Thiazide diuretic usage and risk of fracture: a meta-analysis of cohort studies.

Authors:  X Xiao; Y Xu; Q Wu
Journal:  Osteoporos Int       Date:  2018-03-25       Impact factor: 4.507

9.  The relation between bone and stone formation.

Authors:  Nancy S Krieger; David A Bushinsky
Journal:  Calcif Tissue Int       Date:  2012-12-18       Impact factor: 4.333

10.  Optimal age of commencing and discontinuing thiazide therapy to protect against fractures.

Authors:  C Kruse; P Eiken; P Vestergaard
Journal:  Osteoporos Int       Date:  2015-12-11       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.